anastrozole has been researched along with Endometrioma in 30 studies
Endometrioma: An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole 1 mg/day and/or only Mirena® for 6 months; CS (ovarian and fertility-sparing) or TUGPA of endometriomas one month after starting medical treatment." | 9.41 | Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial. ( Acién, M; Acién, P; Velasco, I, 2021) |
| "Pharmacokinetics (PK) of anastrozole (ATZ) and levonorgestrel (LNG) released from an intravaginal ring (IVR) intended to treat endometriosis symptoms were characterized, and the exposure-response relationship focusing on the development of large ovarian follicle-like structures was investigated by modeling and simulation to support dose selection for further studies." | 9.24 | Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms. ( Nave, R; Ploeger, BA; Reinecke, I; Schmitz, H; Schultze-Mosgau, MH, 2017) |
| "Six months of treatment with anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients following surgery for severe endometriosis." | 9.11 | The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004) |
| "In order to achieve the long-term management of endometriosis, a more economical and environmentally friendly material, ethylene vinyl acetate (EVA), was used to prepare a intravaginal ring with anastrozole (ATZ)." | 8.31 | A novel anastrozole intravaginal ring for endometriosis: Pharmacokinetic characteristics and mucosal irritation. ( Dong, J; Ma, B; Ning, M; Wu, S; Yang, Z, 2023) |
| "To study the effects of aromatase inhibitor (anastrozole) on the growth and estradiol secretion of endometrioma cells in culture." | 7.81 | Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture. ( Badawy, SZ; Brown, S; Kaufman, L; Wojtowycz, MA, 2015) |
| "Although anastrozole, methotrexate, and progesterone were ineffective, 5-FU significantly decreased the proliferation of endometriotic cells in vitro and controlled the growth of both cells from ovarian endometrioma and deep infiltrating endometriosis." | 7.76 | Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. ( Batteux, F; Chapron, C; Chéreau, C; Leconte, M; Ngô, C; Nicco, C; Weill, B, 2010) |
| "To compare the efficacies of anastrozole and raloxifene on endometriosis." | 7.76 | Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. ( Altintas, D; Cetinkaya, MB; Kandemir, B; Kokcu, A; Tosun, M, 2010) |
| "Anastrozole 1 mg/day and/or only Mirena® for 6 months; CS (ovarian and fertility-sparing) or TUGPA of endometriomas one month after starting medical treatment." | 5.41 | Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial. ( Acién, M; Acién, P; Velasco, I, 2021) |
| "Celecoxib was the only treatment to significantly reduce the number of lesions established per mouse, their size and vascularized area." | 5.39 | Anastrozole and celecoxib for endometriosis treatment, good to keep them apart? ( Barañao, RI; Bilotas, MA; Meresman, GF; Olivares, CN; Ricci, AG, 2013) |
| "Pharmacokinetics (PK) of anastrozole (ATZ) and levonorgestrel (LNG) released from an intravaginal ring (IVR) intended to treat endometriosis symptoms were characterized, and the exposure-response relationship focusing on the development of large ovarian follicle-like structures was investigated by modeling and simulation to support dose selection for further studies." | 5.24 | Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms. ( Nave, R; Ploeger, BA; Reinecke, I; Schmitz, H; Schultze-Mosgau, MH, 2017) |
| "Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery." | 5.14 | Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. ( Andersen, AN; Andersen, CY; Bangsbøll, S; Freiesleben, NL; Hartwell, D; Loft, A; Lossl, K; Pedersen, AT, 2009) |
| "Six months of treatment with anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients following surgery for severe endometriosis." | 5.11 | The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004) |
| "In order to achieve the long-term management of endometriosis, a more economical and environmentally friendly material, ethylene vinyl acetate (EVA), was used to prepare a intravaginal ring with anastrozole (ATZ)." | 4.31 | A novel anastrozole intravaginal ring for endometriosis: Pharmacokinetic characteristics and mucosal irritation. ( Dong, J; Ma, B; Ning, M; Wu, S; Yang, Z, 2023) |
| "To study the effects of aromatase inhibitor (anastrozole) on the growth and estradiol secretion of endometrioma cells in culture." | 3.81 | Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture. ( Badawy, SZ; Brown, S; Kaufman, L; Wojtowycz, MA, 2015) |
| "Although anastrozole, methotrexate, and progesterone were ineffective, 5-FU significantly decreased the proliferation of endometriotic cells in vitro and controlled the growth of both cells from ovarian endometrioma and deep infiltrating endometriosis." | 3.76 | Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. ( Batteux, F; Chapron, C; Chéreau, C; Leconte, M; Ngô, C; Nicco, C; Weill, B, 2010) |
| "To compare the efficacies of anastrozole and raloxifene on endometriosis." | 3.76 | Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. ( Altintas, D; Cetinkaya, MB; Kandemir, B; Kokcu, A; Tosun, M, 2010) |
| "Four premenopausal patients with documented refractory endometriosis and chronic pelvic pain were treated with aromatase inhibitors, either anastrazole (3) or letrozole (1), for 6 months." | 3.75 | Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients. ( Konje, JC; Verma, A, 2009) |
| "This is the first case report of successful treatment of severe endometriosis in premenopausal women with the aromatase inhibitor anastrozole combined with P, rofecoxib, and calcitriol." | 3.72 | Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. ( Shippen, ER; West, WJ, 2004) |
| "This treatment for endometriosis is a promising new modality that warrants further investigation." | 2.71 | Anastrazole and oral contraceptives: a novel treatment for endometriosis. ( Amsterdam, LL; Bulun, SE; Gentry, W; Jobanputra, S; Rubin, SD; Wolf, M, 2005) |
| "Endometriosis is defined as the growth of endometrial tissue outside of the uterine cavity." | 2.47 | The emerging use of aromatase inhibitors for endometriosis treatment. ( Nothnick, WB, 2011) |
| " Since endometriosis is a chronic disease, future investigations should clarify whether the long-term administration of AIs is superior to currently available endocrine therapies in terms of improvement of pain, adverse effects and patient satisfaction." | 2.47 | Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. ( Ferrero, S; Gillott, DJ; Remorgida, V; Venturini, PL, 2011) |
| "Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility." | 2.46 | Endometriosis: in search of optimal treatment. ( Nothnick, WB, 2010) |
| "Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility." | 2.45 | Future targets in endometriosis treatment: targeting the endometriotic implant. ( Nothnick, WB; Zhang, X, 2009) |
| "Endometriosis is a relatively common condition in women of reproductive age and is associated with considerable morbidity." | 2.43 | Endometriosis: new genetic approaches and therapy. ( Barlow, DH; Kennedy, S, 2005) |
| "Endometriosis is an oestrogen-dependent, inflammation-driven gynaecologic disorder causing severe disability." | 1.51 | Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model. ( Cohen, M; Marci, R; Pluchino, N; Poppi, G; Tille, JC; Wenger, JM; Yart, L, 2019) |
| " Long-term use of gonadotrophin-releasing hormone analogs, androgenes, and the danazol, which are widely used drugs for endometriosis, is usually not possible due to their suboptimal safety and tolerance profile." | 1.43 | Effect of imatinib on growth of experimental endometriosis in rats. ( Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Seker, M; Yildiz, C, 2016) |
| "Celecoxib was the only treatment to significantly reduce the number of lesions established per mouse, their size and vascularized area." | 1.39 | Anastrozole and celecoxib for endometriosis treatment, good to keep them apart? ( Barañao, RI; Bilotas, MA; Meresman, GF; Olivares, CN; Ricci, AG, 2013) |
| "Treatment with anastrozole or letrozole was started on either postoperative day 1 or 28 and continued for 4 weeks." | 1.36 | Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Stella, I; Sueldo, C, 2010) |
| "Anastrozole was ineffective at preventing deterioration of renal function in this patient." | 1.35 | Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. ( Bohrer, J; Chen, CC; Falcone, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, MP | 1 |
| Potter, BV | 1 |
| Yang, Z | 1 |
| Dong, J | 1 |
| Wu, S | 1 |
| Ma, B | 1 |
| Ning, M | 1 |
| Acién, P | 1 |
| Velasco, I | 1 |
| Acién, M | 1 |
| Nave, R | 3 |
| Klein, S | 2 |
| Müller, A | 1 |
| Chang, X | 1 |
| Höchel, J | 1 |
| Pluchino, N | 1 |
| Poppi, G | 1 |
| Yart, L | 1 |
| Marci, R | 1 |
| Wenger, JM | 1 |
| Tille, JC | 1 |
| Cohen, M | 1 |
| Badawy, SZ | 1 |
| Brown, S | 1 |
| Kaufman, L | 1 |
| Wojtowycz, MA | 1 |
| Yildiz, C | 1 |
| Kacan, T | 1 |
| Akkar, OB | 1 |
| Karakus, S | 1 |
| Seker, M | 1 |
| Kacan, SB | 1 |
| Ozer, H | 1 |
| Cetin, A | 1 |
| Schultze-Mosgau, MH | 2 |
| Waellnitz, K | 1 |
| Kraetzschmar, J | 1 |
| Rautenberg, T | 1 |
| Schmitz, H | 2 |
| Rohde, B | 1 |
| Reinecke, I | 1 |
| Ploeger, BA | 1 |
| Bohrer, J | 1 |
| Chen, CC | 1 |
| Falcone, T | 1 |
| Verma, A | 1 |
| Konje, JC | 1 |
| Lossl, K | 1 |
| Loft, A | 1 |
| Freiesleben, NL | 1 |
| Bangsbøll, S | 1 |
| Andersen, CY | 1 |
| Pedersen, AT | 1 |
| Hartwell, D | 1 |
| Andersen, AN | 1 |
| Nothnick, WB | 3 |
| Zhang, X | 1 |
| Vercellini, P | 1 |
| Crosignani, PG | 1 |
| Somigliana, E | 1 |
| Berlanda, N | 1 |
| Barbara, G | 1 |
| Fedele, L | 1 |
| Bilotas, M | 1 |
| Meresman, G | 1 |
| Stella, I | 1 |
| Sueldo, C | 1 |
| Barañao, RI | 2 |
| Ngô, C | 1 |
| Nicco, C | 1 |
| Leconte, M | 1 |
| Chéreau, C | 1 |
| Weill, B | 1 |
| Batteux, F | 1 |
| Chapron, C | 1 |
| Altintas, D | 1 |
| Kokcu, A | 1 |
| Kandemir, B | 1 |
| Tosun, M | 1 |
| Cetinkaya, MB | 1 |
| Li, A | 1 |
| Wang, Y | 1 |
| Xu, XY | 1 |
| Ferrero, S | 1 |
| Gillott, DJ | 1 |
| Venturini, PL | 1 |
| Remorgida, V | 1 |
| Olivares, CN | 1 |
| Bilotas, MA | 1 |
| Ricci, AG | 1 |
| Meresman, GF | 1 |
| Soysal, S | 1 |
| Soysal, ME | 1 |
| Ozer, S | 1 |
| Gul, N | 1 |
| Gezgin, T | 1 |
| Shippen, ER | 1 |
| West, WJ | 1 |
| Barlow, DH | 1 |
| Kennedy, S | 1 |
| Amsterdam, LL | 1 |
| Gentry, W | 1 |
| Jobanputra, S | 1 |
| Wolf, M | 1 |
| Rubin, SD | 1 |
| Bulun, SE | 4 |
| Hefler, LA | 1 |
| Grimm, C | 1 |
| van Trotsenburg, M | 1 |
| Nagele, F | 1 |
| Takayama, K | 3 |
| Zeitoun, K | 1 |
| Gunby, RT | 1 |
| Sasano, H | 2 |
| Carr, BR | 1 |
| Zeitoun, KM | 1 |
8 reviews available for anastrozole and Endometrioma
| Article | Year |
|---|---|
Future targets in endometriosis treatment: targeting the endometriotic implant.
Topics: Anastrozole; Angiogenesis Inhibitors; Animals; Aromatase Inhibitors; Clinical Trials as Topic; Endom | 2009 |
Medical treatment for rectovaginal endometriosis: what is the evidence?
Topics: Anastrozole; Aromatase Inhibitors; Cohort Studies; Danazol; Endometriosis; Female; Gonadotropin-Rele | 2009 |
Endometriosis: in search of optimal treatment.
Topics: Adalimumab; Anastrozole; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodie | 2010 |
The emerging use of aromatase inhibitors for endometriosis treatment.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Disease Models, Animal; Endometriosis; Endometrium; Estr | 2011 |
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.
Topics: Anastrozole; Aromatase Inhibitors; Clinical Trials as Topic; Endometriosis; Female; Humans; Letrozol | 2011 |
Endometriosis: new genetic approaches and therapy.
Topics: Anastrozole; Aromatase Inhibitors; Drug Therapy, Combination; Endometriosis; Endometrium; Female; Ge | 2005 |
Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Dinoprostone; Endometriosis; Enzyme Inhibitors; Estrog | 2000 |
[Endometriosis and aromatase inhibitor].
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Dinoprostone; Endometriosis; Enzyme Inhibitors; Estrog | 2001 |
7 trials available for anastrozole and Endometrioma
| Article | Year |
|---|---|
Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial.
Topics: Anastrozole; Contraceptive Agents, Female; Endometriosis; Female; Humans; Intrauterine Devices; Intr | 2021 |
Absence of Effect of Intravaginal Miconazole, Clindamycin, Nonoxynol-9, and Tampons on the Pharmacokinetics of an Anastrozole/Levonorgestrel Intravaginal Ring.
Topics: Administration, Intravaginal; Adult; Anastrozole; Anti-Bacterial Agents; Antifungal Agents; Clindamy | 2018 |
Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Topics: Administration, Intravaginal; Adult; Anastrozole; Aromatase Inhibitors; Endometriosis; Estradiol; Fe | 2016 |
Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms.
Topics: Administration, Intravaginal; Adult; Anastrozole; Computer Simulation; Contraceptive Agents, Female; | 2017 |
Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.
Topics: Adult; Anastrozole; Aromatase Inhibitors; CA-125 Antigen; Down-Regulation; Drug Therapy, Combination | 2009 |
The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bone Density; Drug Administration Schedule; Drug Therapy, | 2004 |
Anastrazole and oral contraceptives: a novel treatment for endometriosis.
Topics: Adult; Anastrozole; Contraceptives, Oral; Drug Therapy, Combination; Endometriosis; Female; Humans; | 2005 |
15 other studies available for anastrozole and Endometrioma
| Article | Year |
|---|---|
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
A novel anastrozole intravaginal ring for endometriosis: Pharmacokinetic characteristics and mucosal irritation.
Topics: Anastrozole; Animals; Chromatography, Liquid; Endometriosis; Female; Humans; Reproducibility of Resu | 2023 |
Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Cell Proliferation; Chick Embryo; Chorioallantoic Membra | 2019 |
Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture.
Topics: Anastrozole; Aromatase Inhibitors; Cell Proliferation; Cells, Cultured; Endometriosis; Estradiol; Fe | 2015 |
Effect of imatinib on growth of experimental endometriosis in rats.
Topics: Anastrozole; Angiogenesis Inhibitors; Animals; Aromatase Inhibitors; bcl-2-Associated X Protein; Cel | 2016 |
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Disease Progression; Endometriosis; Female; Humans; Kidney Functi | 2008 |
Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Chronic Disease; Dose-Response Relationship, Drug; Endomet | 2009 |
Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
Topics: Anastrozole; Animals; Apoptosis; Aromatase; Aromatase Inhibitors; Ascitic Fluid; Cell Proliferation; | 2010 |
Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo.
Topics: Adult; Anastrozole; Animals; Antineoplastic Agents; Biopsy; Case-Control Studies; Cell Proliferation | 2010 |
Comparison of the effects of raloxifene and anastrozole on experimental endometriosis.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Disease Models, Animal; Endometriosis; Female; Nitriles; | 2010 |
[Inhibitory effect of Jiawei Sanleng pill medicated serum on estrogen production and its influence on apoptosis of human endometrial cells of endometriosis].
Topics: Anastrozole; Animals; Apoptosis; Cells, Cultured; Dose-Response Relationship, Drug; Drugs, Chinese H | 2010 |
Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Combination | 2013 |
Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Drug Therapy, Combination; Endometriosis; Enzyme Inhibitor | 2004 |
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
Topics: Administration, Intravaginal; Adult; Anastrozole; Aromatase Inhibitors; Chi-Square Distribution; End | 2005 |
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Biopsy; Endometriosis; | 1998 |